Clinical trial
Intensive Versus Conventional Treatment in Patients With Primary Amyloidosis
NCT00344526 · University Hospital, Limoges, Other · Completed
Key facts
| NCT number | NCT00344526 |
|---|---|
| Title | Intensive Versus Conventional Treatment in Patients With Primary Amyloidosis |
| Official title | Autologous Stem Cell Transplantation (ASCT) Versus Oral Melphalan and High-Dose Dexamethasone in Patients With AL (Primary)Amyloidosis. A Prospective Randomized Trial . |
| Lead sponsor | University Hospital, Limoges, Other |
| Collaborators | Ministry of Health, France |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Primary Systemic Amyloidosis (AL) |
| Intervention type | Drug, Procedure |
| Interventions | Melphalan, Dexamethasone, Autologous stem cell transplantation |
| Enrollment | 100 |
| Start date | Jan 1, 2000 |
| Completion | Jun 1, 2006 |
| First posted | Jun 26, 2006 |
| Last update posted | Jun 28, 2007 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: